SUMMARY OF PRODUCT CHARACTERISTICS

1. Name of the veterinary medicinal product

Streptacare Suspension for Injection

2. Qualitative and quantitative composition

Active Substance:

Each ml contains:

Procaine penicillin 200 mg

Dihydrostreptomycin Sulfate 250 mg

Excipients:

Hydroxybenzoate Esters (Nipasept sodium) 1.5 mg

[as antimicrobial preservatives

methyl parahydroxybenzoate 1.07 mg*

ethyl parahydroxybenzoate 0.25 mg*

propyl parahydroxybenzoate 0.145 mg*

(* as approximate amounts)]

Sodium formaldehyde sulphoxylate dihydrate as antioxidant 1.25 mg.

For a full list of excipients, see section 6.1

3. Pharmaceutical form

Suspension for injection.

A white to off-white suspension.

4. Clinical Particulars

4.1 Target species

Cattle

Horses

Sheep

Pigs

4.2 Indications for use, specifying the target species

For the treatment of systemic infections in cattle, horses, sheep and pigs caused by or associated with organisms sensitive to penicillin and/or streptomycin including:

Arcanobacterium pyogenes

Erysipelothrix rhusiopathiae

Klebsiella pneumoniae

Listeriaspp

Mannheimia haemolytica

Pasteurella multocida

Staphylococcusspp (non-penicillinase producing)

Streptococcusspp

Salmonellaspp

And for the control of secondary bacterial infection with sensitive organisms in diseases primarily associated with viral infection.

4.3 Contra-indications

Contraindicated in known cases of hypersensitivity to penicillins.

4.4 Special Warnings for each target species

Use with care in animals known to have kidney disease or defective renal function.

Do not exceed the recommended dosage or duration of treatment.

4.5 Special precautions for use

Wherever possible, use of Streptacare should be based on susceptibility testing.

Care should be taken not to exceed the recommended dosage. Aminoglycosides have a narrower margin of safety than beta lactam antibiotics.

Care should be taken to avoid accidental self-injection. In case of accidental self-injection, seek medical advice immediately.

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporins and vice versa. Allergic reaction to these substances may occasionally be serious.

1. Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.

2. Handle this product with great care to avoid exposure taking all recommended precautions.

3. If you develop symptoms following exposure, such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.

Wash hands after use.

4.6 Adverse reactions (frequency and seriousness)

Occasionally in sucking and fattening pigs, administration may cause a transient pyrexia, vomiting, shivering, listlessness and in-coordination.

A palpable but transient local reaction may occur at the site of intramuscular administration in horses. Additionally in pregnant sows and gilts, a vulval discharge which could be associated with abortion has been reported.

4.7 Use during pregnancy, lactation or lay

Streptacare can be safely administered to pregnant and lactating animals. However in pregnant sows and gilts a vulval discharge which could be associated with abortion has been reported.

4.8 Interaction with other medicinal products and other forms of interaction

Do not administer with other antibiotics such as tetracyclines or with other aminoglycosides.

4.9 Amounts to be administered and administration route

Shake the vial before use.

Administer by deep intramuscular injection.

Recommended dosage rate is 8 mg/kg bodyweight procaine penicillin with 10 mg/kg bodyweight dihydrostreptomycin sulphate equivalent to 1 ml per 25 kg bodyweight. Treatment should be given once daily for up to 3 consecutive days. The maximum dose volume administered at one site should not exceed 15 ml for horses, 6 ml for cattle, 3 ml for sheep and 1.5 ml for pigs.

No treatment specified.

Not to be used in sheep producing milk for human consumption.

Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken from cows after 60 hours from the last treatment.

Animals must not be slaughtered for human consumption during treatment.

Cattle intended for human consumption should not be slaughtered until 23 days after the last treatment. Pigs intended for human consumption should not be slaughtered until 18 days after the last treatment. Sheep intended for human consumption should not be slaughtered until 31 days after the last treatment.

Not to be used in horses intended for human consumption.

Treated horses may never be slaughtered for human consumption.

The horse must have been declared as not intended for human consumption under national horse passport legislation.

5. pharmacological properties

Pharmacotherapeutic group: Antibacterial

ATC Vet Code: QJ01RA01

5.1 Pharmacodynamic properties

Penicillin G is a beta-lactam antibiotic and its structure contains the beta-lactam ring and thiazolidine ring common to all penicillins. Beta-lactam antibiotics prevent the bacterial cell wall of susceptible Gram-positive bacteria from forming by interfering with the final stage of peptidoglycan synthesis. They inhibit the activity of transpeptidase enzymes, which catalyse cross-linkage of the glycopeptide polymer units that form the cell wall. They exert a bactericidal action but cause lysis only of growing cells.

Dihydrostreptomycin is an aminoglycoside antibiotic active against gram-negative aerobes, which after penetration of the cell envelope binds to receptors on the 30S sub unit of the bacterial ribosome. It induces misreading of the genetic code on the messenger ribonucleic acid (mRNA) template, causing bacteriostasis. Aminoglycosides exert synergistic action in combination with beta-lactam antibiotics.

5.2 Pharmacokinetic properties

After injection of Streptacare, the procaine penicillin is rapidly absorbed from the site of injection, with maximum penicillin levels of between 1 and 2 µg/ml for horses, sheep and pigs and 0.5 µg/ml for cattle, being obtained within 2 hours of injection.

The penicillin elimination half-lives are approximately 2 hours for sheep and pigs, 5 hours for cattle and 11 hours for horses. Dihydrostreptomycin is absorbed at a similar rate, with maximum plasma levels of 23 µg/ml being obtained for cattle, sheep and pigs, and 15 µg/ml for horses. The elimination half-lives are approximately 2 hours for cattle, sheep and pigs and 4 hours for horses.

6. Pharmaceutical particulars

6.1 List of excipients

Sodium formaldehyde sulphoxylate dihydrate

M ethyl parahydroxybenzoate

Ethyl parahydroxybenzoate as Nipasept sodium

Propyl parahydroxybenzoate

Povidone K12

Polysorbate 80

Sodium Citrate Dihydrate

Disodium Edetate Dihydrate

Procaine Hydrochloride

Cetrimide

Citric acid anhydrous

Water for injection

6.2 Incompatibilities

None known

Shelf life of the veterinary medicinal product as packaged for sale:

Glass: 9 months, Plastic: 2 years

Shelf life after first opening the immediate packaging: 28 days.

Glass: Do not store above 25C.

Plastic: Store between 2 - 8C

Protect from light.

Following withdrawal of the first dose, use the product within 28 days.

Discard unused material.

Clear type II multidose glass vials of 50 ml and 100 ml, sealed with bromobutyl bungs.

Clear polyethylene terephthalate plastic vials of 50 ml, 100 ml and 250 ml sealed with bromobutyl bungs and aluminium caps.

Not all pack sizes may be marketed.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirement.

7. MARKETING AUTHORISATION HOLDER

Norbrook Laboratories Limited

Station Works

Camlough Road

Newry

Co. Down

BT35 6JP

Northern Ireland

8. MARKETING AUTHORISATION NUMBER

Vm:02000/4155

9. DATE OF FIRST AUTHORISATION

Date:30 April 1998

10. DATE OF REVISION OF THE TEXT

Date: September 2014

Approved: 10/09/2014